Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

医学 临床试验 医学物理学 淋巴瘤 可比性 淋巴结 实体瘤疗效评价标准 肿瘤科 内科学 放射科 临床研究阶段 数学 组合数学
作者
Bruce D. Cheson,Sandra J. Horning,B Coiffier,Margaret A. Shipp,Richard I. Fisher,Joseph M. Connors,Tim Lister,Julie M. Vose,Antonio J Grillo-López,Anton Hagenbeek,Fernando Cabanillas,Donald Klippensten,Wolfgang Hiddemann,Ronald A. Castellino,Nancy L. Harris,Jamés O. Armitage,William Carter,Richard T. Hoppe,George P. Canellos
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:17 (4): 1244-1244 被引量:3470
标识
DOI:10.1200/jco.1999.17.4.1244
摘要

ABSTRACT: Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL). To achieve this, two meetings were convened among United States and international lymphoma experts representing medical hematology/oncology, radiology, radiation oncology, and pathology to review currently used response definitions and to develop a uniform set of criteria for assessing response in clinical trials. The criteria that were developed include anatomic definitions of response, with normal lymph node size after treatment of 1.5 cm in the longest transverse diameter by computer-assisted tomography scan. A designation of complete response/unconfirmed was adopted to include patients with a greater than 75% reduction in tumor size after therapy but with a residual mass, to include patients—especially those with large-cell NHL—who may not have residual disease. Single-photon emission computed tomography gallium scans are encouraged as a valuable adjunct to assessment of patients with large-cell NHL, but such scans require appropriate expertise. Flow cytometric, cytogenetic, and molecular studies are not currently included in response definitions. Response rates may be the most important objective in phase II trials where the activity of a new agent is important and may provide support for approval by regulatory agencies. However, the goals of most phase III trials are to identify therapies that will prolong the progression-free survival, if not the overall survival, of the treated patients. We hope that these guidelines will serve to improve communication among investigators and comparability among clinical trials until clinically relevant laboratory and imaging studies are identified and become more widely available.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
3秒前
3秒前
Owen应助jocelyn采纳,获得10
4秒前
奋斗的不言完成签到,获得积分20
5秒前
cream完成签到,获得积分10
6秒前
7秒前
萌萌发布了新的文献求助10
7秒前
8秒前
8秒前
8秒前
优雅的帅哥完成签到 ,获得积分20
8秒前
空白完成签到,获得积分10
9秒前
11秒前
13秒前
13秒前
nulinuli完成签到 ,获得积分10
13秒前
光亮丹琴完成签到,获得积分10
13秒前
13秒前
14秒前
打打应助飞飞采纳,获得10
14秒前
谨慎珊完成签到,获得积分10
15秒前
无奈的代珊完成签到 ,获得积分10
15秒前
晚灯君完成签到 ,获得积分10
15秒前
16秒前
dan发布了新的文献求助30
17秒前
Three完成签到,获得积分10
17秒前
18秒前
云瑾应助revew666采纳,获得30
18秒前
ZZzz完成签到 ,获得积分10
18秒前
19秒前
19秒前
qll完成签到,获得积分10
19秒前
LKIU完成签到 ,获得积分10
19秒前
20秒前
金鱼的眼泪完成签到,获得积分10
20秒前
21秒前
研友_8DoPDZ完成签到,获得积分10
22秒前
共享精神应助袁大头采纳,获得10
22秒前
23秒前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Handbook of Qualitative Cross-Cultural Research Methods 600
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137214
求助须知:如何正确求助?哪些是违规求助? 2788251
关于积分的说明 7785413
捐赠科研通 2444284
什么是DOI,文献DOI怎么找? 1299869
科研通“疑难数据库(出版商)”最低求助积分说明 625639
版权声明 601023